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Widely differing views exist amongst experts, policy makers and the general public, regarding 2 
the potential risks and benefits of reduced- or low-energy sweeteners (LES) in the diet. 3 
These views are informed and influenced by different types of research in LES, with differing 4 
hypotheses, designs, interpretation and communication. Given the high level of interest in 5 
LES, and the public health relevance of the research evidence base, it is important that all 6 
aspects of the research process are framed and reported in an appropriate and balanced 7 
manner. In this perspective, we identify and give examples of a number of issues relating to 8 
research and reviews on LES, which may contribute toward apparent inconsistencies in the 9 
content and understanding of the totality of evidence. We conclude with a set of 10 
recommendations for authors, reviewers and journal editors, as general guidance to improve 11 
and better standardize the quality of LES research design, interpretation, and reporting. 12 
These focus on clarity of underlying hypotheses, characterization of exposures, and the 13 
placement and weighting of new research within the wider context of related prior work.  14 
 15 
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Research and review papers convey a range of differing conclusions about the potential 17 
impact of low-energy (‘artificial’ or nature-derived) sweeteners (LES) on public health, 18 
ranging from harmful to neutral to beneficial. Some commentators have highlighted concerns 19 
that use of LES may raise risks for obesity and metabolic disorders (1-4), while others are 20 
equally clear in expressing likely benefits of LES with regard to many of these same 21 
outcomes (5, 6). This has not been resolved by recent systematic reviews with meta-22 
analyses (7-9), which generated differing conclusions. 23 
There is consistent international guidance to industry and the public to reduce sugars intakes 24 
(10), and LES are a major alternative to sugars in many products, making this is an important 25 
public health issue to resolve. Furthermore, given that LES and LES-containing products 26 
receive a high level of attention from media and consumers, there is additional responsibility 27 
for experts to frame and communicate their views and research data in an appropriate 28 
context. As such, high standards for research designs and the representation and weighting 29 
of evidence are needed to ensure a balanced interpretation, context and reporting in 30 
research and reviews on LES.  31 
A recent expert stakeholder panel proposed a number of research priorities for LES and 32 
health outcomes (11). While that panel did not specifically address issues relating to the 33 
execution of research and reporting on LES, others have highlighted issues in experimental 34 
design and interpretation that can magnify apparent inconsistencies in the evidence base 35 
(12-14). In this commentary, we highlight specific practices which can be considered as part 36 
of guidance to improve the design, reporting and interpretation of research on LES. We 37 
illustrate the issues with examples, and conclude with some recommended practices for 38 




Be clear about the hypothesis: What question is being tested?  41 
From a public health perspective there is need for an evidence base of research that 42 
decisively addresses the benefits and risks of LES, i.e. generating reliable data and analyses 43 
on how the use of LES, as a replacement for sugars or on their own, influence metabolic 44 
health. Research on LES and non-communicable disease risks fit broadly under 3 underlying 45 
a priori hypotheses, reflecting questions about exposure to energy reduction, sweetness or 46 
LES-specific (metabolic or safety) effects. The design of studies, particularly in terms of the 47 
exposure and relevant comparators, should follow from and correspond to the underlying 48 
hypothesis and primary research question being posed. 49 
 50 
1) Energy reduction: Testing effects of low-/non-caloric vs caloric sweeteners 51 
Where the research question tests exposure to LES as a generic low- or non-caloric 52 
source of sweetness, the hypothesis as stated is usually independent of the specific 53 
sweetener(s) considered. The appropriate comparator will be the same test product 54 
(usually food or beverage) vehicle(s) or dietary regimen with caloric sweeteners, tested 55 
against LES with a significantly lower energy content per unit consumed, and similar in 56 
sweetness and other sensory attributes. 57 
 58 
2) Sweetness: Testing effects of sweetness (sweet stimuli) exposure per se  59 
Where the research question tests exposure to LES as a ‘pure’ (non-caloric) sweet 60 
stimulus, the hypothesis as stated is usually independent of the specific sweetener(s) 61 
considered. The main exception to this would where the hypothesis is based on to 62 
interactions of a specific LES structure and sweet taste receptor(s). The appropriate 63 
comparison is to exposure to the same or similar delivery vehicle(s) or dietary regimen, at 64 
the same energy and nutrient density, with and without LES.  65 
Depending on the hypothesis, the research may test oral exposure to LES as sweet 66 
stimulus, or LES as chemical stimuli for receptors sensitive to ‘sweet’ tastants in the gut or 67 
internal tissues. For oral exposure, the most common comparison would be LES-68 
 
 
sweetened beverages vs water, but this has also been tested with solid foods (15). To 69 
isolate the post-oral gastrointestinal or systemic exposures, LES in capsules would 70 
typically be used, or perhaps nasoenteric intubation (16) .  71 
In order to interpret whether any putative effects are a response to LES specifically vs 72 
sweet stimuli in general, these studies should optimally include an additional comparison 73 
of sweet vs non-sweet caloric stimuli, such as glucose (sweet) vs pure short-chain 74 
maltodextrin (non-sweet, rapidly hydrolyzed glucose polymer). 75 
 76 
3) Sweetener-specific: Testing specific post-ingestive (metabolic, physiological, toxicologic) 77 
effects of a specific LES or group of LES 78 
These types of research questions are clearly based around one or more specific LES, 79 
with the underlying hypothesis relating to unique physiological effects that may arise from 80 
their particular characteristics. In this case the appropriate comparison is to the same test 81 
product (food, beverage, capsule) vehicle(s) or dietary regimen with no LES or, to sharpen 82 
the interpretation, preferably a different LES lacking the characteristic(s) of interest. 83 
Because sweeteners differ markedly in their absorption, distribution, metabolism and 84 
excretion (ADME), they can also differ in the potential presence of the intact material or 85 
metabolites in different body sites (17, 18). This point is often overlooked, yet may be 86 
highly relevant for the interpretation and extrapolation of experimental and population 87 
data, and is considered further in the next section.  88 
 89 
Differences in the (stated or unstated) hypotheses, lack of clarity or mixing of hypotheses can 90 
have important consequences. Examples of this can be seen in the assessment of effects of 91 
LES intervention trials on outcomes relating to energy balance in 3 recent systematic reviews 92 
with meta-analyses. Rogers et al (8) separately analyzed and reported comparisons of LES 93 
vs sugars, LES vs water, and LES vs placebo capsules. In contrast, Azad et al. (7) and 94 
Toews et al. (9) did not make this distinction between comparators. For energy intake and 95 
weight change, a benefit of LES is more plausible when compared to a caloric than a non-96 
 
 
caloric alternative (19), so the decision of whether to make this distinction can significantly 97 
impact the combined effect sizes and conclusions (as can be seen in those reviews). There 98 
may be valid arguments for either approach in meta-analysis; however, the primary research 99 
studies invariably differentiate these comparisons in their hypotheses and designs.  100 
A further consideration is whether the underlying hypotheses are or should be sweetener-101 
specific. This has implications for study selection and the interpretation (extrapolation) of 102 
results. For example, the protocol and objectives for the systematic review of Toews (9) are 103 
framed in a way that is independent of the specific sweetener, although the review only 104 
included studies where the sweetener was specified. This criterion largely excludes studies 105 
where free-living subjects consume a mix of commercial LES-containing ‘diet’ products, 106 
generating much smaller evidence base than other contemporary systematic reviews for 107 
similar outcomes (7, 8, 20).  108 
 109 
Control and specify exposures where relevant  110 
There are research hypotheses and designs where the nature of the exposure and specific 111 
LES may be important. By definition, LES all share the characteristics of being sweet and low 112 
in energy when used in place of sugars. For hypotheses based on exposure to energy or 113 
sweetness, effects are usually assumed to be related to variation in the energy content or 114 
taste attributes of the test materials (19, 21). In the absence of other hypotheses, it is 115 
generally reasonable to presume that similar results would be seen using other LES to 116 
achieve the same calorie reduction or taste profile. Nevertheless, specific LES may differ 117 
with regard to their stimulation of different “sweet taste” receptors, digestion or uptake in the 118 
gut, and appearance and pharmacokinetics in different body pools, which results in differing 119 
potential for interactions with specific gut or systemic receptors and systemic or gut 120 
(including microbiota) metabolism (14, 17, 18, 22, 23). For example, protein or peptide 121 
sweeteners are rapidly digested and absorbed as their constituent amino acids, so will not 122 
enter the colon. Sucralose is usually reported to be almost completely excreted intact in 123 
feces (70-90%), although this has recently been questioned (24). Steviol glycosides on the 124 
 
 
other hand are actively metabolized by the colonic microflora, bacterial cleavage of the 125 
glycoside component allowing absorption of steviol which is systemically available after 126 
hepatic glucuronidation and renally excreted.  127 
There is currently considerable interest in the possible effects of LES on the gut microbiota 128 
composition, which has been reported for saccharin, sucralose and steviol glycosides in 129 
humans (25). The plausibility of these observations is directly linked to the molecular and 130 
thus ADME properties of the specific LES, and cannot be generalized. Moreover, as the 131 
functional capacity of the microbiota may be more relevant than purely taxonomic accounts 132 
of composition, the extrapolation from these observations to health implications must also 133 
take account of the nature and properties of the specific LES exposures. The majority of 134 
these studies have also been in rodents, which have been valuable in generating new 135 
hypotheses, especially where these are not amenable to direct testing in humans (e.g., 26). 136 
However, important differences in specific animal research models and test conditions 137 
contribute to many inconsistencies in this literature (12, 27), and direct relevance to human 138 
nutrition and metabolism cannot simply be assumed. Approaches in animal studies such as 139 
very excessive dose loading may be appropriate for some safety and toxicological research 140 
but can have distorting consequences for nutrition-related outcomes. A further issue for 141 
interpretation and replication is that many studies have fed animals commercial ‘tabletop’ 142 
LES preparations which are of unknown, impure or variable composition, where the 143 
sweetener comprises perhaps only a small percentage of the total content (28-30). Notably, 144 
the non-LES filler material or bulking agents in these compositions may also include 145 
fermentable carbohydrates.  146 
Exposures in studies may be short- or long-term, and hypotheses should also logically relate 147 
to this. Despite in vitro evidence of variation in stimulation of oral, gut and systemic receptors 148 
by LES, a large body of short-term physiological studies in humans find no consistent generic 149 
or LES-specific effect on acute postprandial responses (31-33). However, there is more 150 
limited evidence testing potential variation in chronic LES-specific exposure effects on 151 
glycemic or gut hormone responses. Here it would be crucial that hypotheses relate to the 152 
 
 
metabolic fates of specific LES, which might differentially affect physiology in the long-term, a 153 
different and possibly more important question than what single-dose acute studies can 154 
address. Measurable differences in physiological responses to different LES, mediated by 155 
mechanisms independent of their actions at sweetness receptors, may be almost inevitable 156 
given their extreme chemical diversity. It is important to confirm whether these differences 157 
produce consistent and meaningful variation in health-related outcomes (34). 158 
Depending on the hypotheses, human research studies may also need to take account (e.g. 159 
by selection or pre-planned statistical analyses) of participant characteristics, particularly 160 
whether they are habitually high or low consumers of LES. It is likely that these groups also 161 
differ in regard to other habitual dietary and other lifestyle behaviors or personal 162 
characteristics (e.g. microbiome), which may significantly influence responses to 163 
interventions or their interpretation (14, 18). Establishing the nature of prior LES exposures of 164 
populations may also have important implications for the interpretation of cross-sectional and 165 
prospective observational studies measuring birth or long-term health outcomes. It seems 166 
essential (and yet is rare) that researchers consider which particular LES were available to 167 
the cohort at the time and place of data collection or index events (such as conception, 168 
pregnancy), so the plausibility of causal interpretations can be placed in the context of the 169 
relevant ADME properties and prior physiological or safety studies. For example, as noted 170 
above, LES differ substantially in their uptake and access to systemic circulation or tissues. 171 
Lastly, a limitation noted in a recent systematic review of the relationship between sweet 172 
taste exposure and subsequent liking and preference for sweet stimuli was that few studies 173 
had made any quantitative assessments of the perceived sweetness of test materials or diets  174 
(21). Instead, the content or even just the presence of sugars or sweeteners in foods or diets 175 
was often used as a proxy indicator of exposures to sweetness. While matching of test 176 
materials should be relatively easy in laboratory-based trials, the characterization of 177 
exposures to sweetness is more challenging where the subjects or cohort are consuming a 178 
range of commercially available foods. Recent efforts to generate “sensory-diet” databases 179 
(35, 36) are an important development, as they can provide a basis for objectively quantifying 180 
 
 
and comparing exposures to sensory attributes of foods and diets in large populations. For 181 
both behavioral and physiological research focused on the effects of orosensory exposure to 182 
sweetness in foods or beverages, it seems essential that some effort is made to verify the 183 
actual exposures. 184 
Considering all these potential sources of variability in research materials or exposures, 185 
design and outcomes, it is vital that the hypotheses, design and interpretation of research are 186 
consistent with the specific LES source(s), the doses and means of delivery, and the putative 187 
mechanisms or sites of action, which may primarily be oral, gastrointestinal or systemic. 188 
Effects of specific sweeteners may be independent of sweetness, even where this is the 189 
main attribute of LES that underpins the reason to design and undertake the study. 190 
Depending on the hypothesis, the range of potential “off-target” effects may make it 191 
inappropriate to aggregate LES studies together and test for a class effect. 192 
 193 
Place new research in the context of the totality of evidence 194 
New or different types of research will have differing contributions to the overall totality of 195 
evidence, and should be viewed within this context (37). The impartial and balanced 196 
representation and dissemination of the evidence base can however be undermined by 197 
selective citation and citation distortion (citation bias and amplification) in biomedical 198 
research (38, 39). These practices include systematically ignoring data conflicting with prior 199 
beliefs, conveying hypothesis as fact, and preferential reference to statistically significant vs 200 
“neutral” outcomes (or vice-versa).  201 
Reporting of research on LES is not immune to these issues. An extreme example is the 202 
pattern of citations to Suez et al (29), who proposed that consumption of intense sweeteners 203 
may alter the intestinal microbiota leading to adverse effects on glucose tolerance. As of 204 
November 2019 that publication had been cited over 1000 times, usually to highlight this as a 205 
potential or even confirmed risk of LES (2, 4, 40). In contrast, a 2013 systematic review of 206 
controlled human trials of LES effects on markers of glycemic control (41), with a differing 207 
conclusion, had been cited only 5 times. Similarly, reviews of the LES-microbiota-glycemia 208 
 
 
hypothesis (e.g., 42) may also make little or no reference at all to the primary research 209 
papers and reviews of controlled human trials that have specifically tested sustained 210 
exposure to LES on glycemic control (32, 43, 44), nor the regulatory and safety reviews 211 
where these outcomes have been considered in depth for specific sweeteners (18, 45-49).  212 
The choice of this example is not to question the results of Suez et al (29) or whether LES 213 
affect microbiota or glycemic control. It is simply to illustrate where new research with 214 
provocative results needs to be placed in the context of the totality of prior evidence. In this 215 
case, the record of citations indicates a pattern of giving disproportionate weight to 216 
hypothesized adverse effects, relative to a large body of empirical evidence to the contrary 217 
(18). In other cases, hypothesized effects of LES are simply assumed, with seemingly no 218 
apparent need to consider the evidence at all. For example, a common argument against the 219 
use of LES as an approach to reduce sugars intakes, rests on the view that sweetness 220 
exposure ‘drives’ sweetness preferences. This idea is plausible and commonly expressed, 221 
and even appears in relatively high-level policy documents (50). Yet there seems to be little 222 
objective support for this view, and possibly even more evidence favoring the alternative that 223 
sweetness exposure satisfies (rather than drives) preferences (21).  224 
The persistent failure to present and consider research in the context of the totality of prior 225 
evidence risks uncritically (re-)generating and sustaining hypotheses without adequately 226 
acknowledging where these have previously been robustly tested and perhaps rejected (see 227 
51). From recent headlines, commentaries and narrative reviews, non-experts might be 228 
forgiven for being unaware that LES had been the subject of a substantial number of RCTs, 229 
and systematic reviews and meta-analyses of these. As a general principle, it is poor practice 230 
for professional papers to cite selected in vitro, animal and observational studies as the 231 
primary evidence for putative effects of LES, without balanced reference to the large corpus 232 
of human trials and safety assessments where the same markers and outcomes have been 233 
considered (45-49). When the totality of information is considered a very different picture 234 
may emerge. For example, animal data are often used to underpin the view that LES may 235 
lead to disordered appetite and weight gain. However, in our systematic review of human 236 
 
 
and animal studies of LES and body weight (8), we identified 90 relevant animal studies of 237 
which only a small minority (mostly from one research group) reported increased body 238 
weight. The corresponding human RCT data also showed beneficial effects on energy intake 239 
and body weight. The impact of selective citation is reflected in the view of some members of 240 
a recent expert stakeholder panel, that additional LES intervention trials for weight control 241 
outcomes were mainly needed “…due to public perception and some vocal opposition” (11). 242 
 243 
Acknowledge the limitations of observational and animal data 244 
Even papers critical of LES acknowledge there are many discrepancies between the adverse 245 
health impacts hypothesized by some animal and human observational studies, in contrast to 246 
more often neutral or beneficial effects usually seen in human intervention trials (52). 247 
Differences in the weighting given to evidence from these different research designs 248 
contributes toward differing views of the perceived risks and benefits of LES. While there are 249 
limitations to the suitability and interpretation of RCT data for certain research questions (37), 250 
there is a need for particular caution in selective use and extrapolation from observational 251 
and animal data. This can be illustrated by the interpretation of research on the relationship 252 
between water intake and body weight, as an analogy to research on LES.  253 
Water is a zero-energy food and beverage ingredient, widely recommended as a preferred 254 
beverage choice in the context of obesity, despite inconsistent evidence around its influence 255 
on weight management (53). Systematic reviews and meta-analyses of observational data 256 
on water consumption in relation to weight management have reported limited evidence of 257 
benefits, and even significant adverse associations of water consumption with body weight 258 
outcomes in children and adolescents (54, 55). Other analyses have found that water 259 
consumption was positively associated with all-cause mortality (56). The plausibility of 260 
adverse effects of water consumption on weight control could be further supported by 261 
reference to a considerable volume of animal research. It has long been known that greater 262 
water intake is positively correlated with greater food intake in animals (57), and greater 263 
 
 
weight gain with the addition of water to the diet has been reported in experiments with 264 
several species (58-63).  265 
This example shows the ease with which selective, uncritical reference to observational and 266 
animal research could be used to underpin an apparently compelling but intentionally absurd 267 
narrative. In the case of water, adverse effects suggested by the cited observational and 268 
animal studies are readily dismissed, despite the absence of a robust body of contrary RCT 269 
data. For LES, similar adverse effects suggested by observational and animal data are given 270 
much more weight as a basis for causal inferences, even where there are substantial RCT 271 
data to the contrary. There may be very valid reasons for this, but animal studies may lack 272 
generalizability (27, 64), and the limitations of observational studies and risk of assuming 273 
causation from association are well-known (65, 66). In the observational studies of water and 274 
body weight, confounding and reverse causality are readily invoked and accepted as reasons 275 
to conclude the observed relationships are spurious (54, 56, 67). Similar concerns have 276 
repeatedly been raised regarding interpretation of epidemiological associations of body 277 
weight and metabolic health with LES (3, 13, 68). LES may be disproportionately used in 278 
place of sugar by individuals with a pre-existing history or elevated risk of weight gain or 279 
diabetes, and this caveat is often highlighted in the original papers (e.g., 69). Moreover, in 280 
the case of LES, the likelihood that epidemiological associations are specious is reinforced 281 
where the corresponding RCT data for related outcomes consistently indicate neutral or 282 
beneficial effects (8, 41). As a result, several authors have expressed doubt about the weight 283 
that should be placed on observational (and animal) studies in this area for outcomes where 284 
data from sustained RCTs are available (8, 13, 70, 71).  285 
This ultimately comes down to ensuring the research approach has been appropriately 286 
designed to address a specific hypothesis, and that the limitations - including potential for 287 
confounding or post-hoc use of the same data to answer other research questions - are 288 
adequately acknowledged in drawing conclusions. All types of study designs have potential 289 
weaknesses, and all can contribute in different ways to the totality of evidence (37). 290 
Observational and animal research on LES can generate hypotheses and address questions 291 
 
 
that cannot be directly tested in humans, such as longer-term disease outcomes and 292 
toxicology, and potential multi-generational effects (26, 27, 72, 73). Nevertheless, such data 293 
should be very cautiously interpreted, particularly where they conflict with results from robust 294 
RCTs.  295 
 296 
A note on bias: white hats and black hats 297 
Application of the guidance proposed here would improve the quality of communication and 298 
discourse on LES, independent of the views or interests of who is delivering the messages. 299 
All stakeholders may potentially be guilty of “white hat bias”, the well-intentioned but biased 300 
“distortion of information in the service of what may be perceived to be righteous ends” (74). 301 
We as authors hold certain views based on our reading of the evidence and our own 302 
research (8, 19, 21), and also acknowledge potential conflicts of interest such as funding 303 
sources and collaborations. In research on LES, as in other areas of nutrition, the potential 304 
for industry-related (“black hat”) bias has been widely discussed. Indeed, Mandrioli et al (75) 305 
recently concluded that reviews of LES and health were biased by sponsorship and financial 306 
conflicts of interest, although the risk of bias was mainly relevant to narrative rather than 307 
systematic reviews. However, commercial associations are not the only possible source of 308 
bias, and absence of such interests is no assurance of impartiality (39, 74, 76-79). The 309 
personal reputation, conference invitations, and travel and research support for 310 
“independent” researchers may also benefit from the particular views they take. A continued 311 
flow of provocative research results and atmosphere of uncertainty around LES undoubtedly 312 
also improves the chances for further funding of research on the topic.  313 
These different biases can influence the design, interpretation, and reporting of research on 314 
LES, undermining an impartial and balanced scientific and public consideration of the 315 
possible benefits or risks of their use. This places even greater demand on authors and 316 
journal editors to ensure the faithful representation and appropriate weighing of evidence. 317 
With this in mind, we encourage others, and especially those with differing views, to offer 318 
 
 
other examples from the current literature that would support further refinement of the 319 
recommendations that follow here. 320 
 321 
Conclusions and recommendations  322 
There are significant issues in how the evidence base on LES is generated, interpreted and 323 
communicated by the expert community, with implications for public health, industry and 324 
future research needs. We have discussed a number of these, with examples, to illustrate 325 
the need for a more consistent standard of practice in the conceptualization and reporting of 326 
both primary research and reviews of that research. These issues also emphasize areas for 327 
more careful and critical scrutiny of research publications by wider stakeholders, including 328 
research end-users. 329 
Importantly, in relation to public health, LES are not a case where the “precautionary 330 
principle” necessarily applies. Where adverse effects of LES exposures are confirmed by 331 
evidence-based expert risk assessment, these rightly should be considered in regulatory and 332 
public health policies. However, there may also be value gained from the use of LES, for 333 
example as a tool for maintaining the acceptability of foods, beverages and diets reduced in 334 
sugar, facilitating progress towards widely-advised goals to reduce sugar intakes (80, 81). In 335 
short, there are risks to be considered not just from exposure to LES but also from 336 
prematurely advising the public to avoid them. 337 
We believe it should be possible to formulate guidance to address the issues raised here, 338 
which can be widely embraced by individual researchers, and those involved with the 339 
funding, communication and use of research. Many of our concluding recommendations in 340 
Table 1 apply to nutrition research in general, but they have particular relevance to research 341 
with LES. We hope these can be broadly accepted by the expert community, and welcome 342 
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Table 1. Recommendations for research and reporting on LES 
• Research hypotheses should be explicit, and the underlying research question(s) 
reflected in the choice of exposures, comparators and analyses. 
• The justification and interpretation of primary research studies and their 
representation in reviews should reflect the stated hypotheses, with particular regard 
to caloric vs non-caloric comparators, and potential for extrapolation to LES in 
general vs specific LES.  
• Where outcomes are not attributable to energy reduction or perceived sweetness, 
interpretation relies on the chemical and ADME properties of specific LES.   
• The selection and citation of existing research should fairly represent the balance 
and weight of different types of evidence, particularly where there are data from 
RCTs with relevant exposures and populations.  
• Animal research and other studies generating evidence related to safety and 
toxicology should specifically refer to that literature. 
• Reporting of evidence on health associations with LES from observational studies, 
including prospective cohort studies, should be clear that these are subject to 
residual confounding including reverse causality, and may have been designed to 
answer a different research question. 
• Hypotheses generated by observational and animal data must be interpreted in 
relation to the specific exposures, plausible causal pathways, and results of any 
related human intervention trials. 
